The study examines variations of serum interleukin (IL)-6, IL-17, and transforming growth factor-β (TGF-β) in pediatric viral myocarditis. One hundred and twenty children diagnosed with acute viral myocarditis were divided into survival (n = 60) and death (n = 60) groups according to their prognosis. Troponin I, serum IL-6, IL-17, TGF-β, creatine kinase isoenzyme MB, and brain natriuretic peptide levels were significantly increased on admission and gradually increased during 1 week of immune monitoring, of which TGF-β and IL-6 peaked in the second week and IL-17 peaked in the fourth week. The above-mentioned indices were significantly lower in the survival group than those in the death group (P < .05). The survival group exhibited significantly higher left ventricular ejection fraction (LVEF) (P < .05) and significantly lower brain natriuretic peptide (BNP) level (t = −0.408, P = .72) than the death group. The serum levels of IL-6, IL-17, and TGF-β were significantly increased in children with acute viral myocarditis, and the LVEF was the main influencing factor leading to poor prognosis.
GinsbergFParrilloJE.Fulminant myocarditis. Crit Care Clin. 2013;29(3):465-483. doi:10.1016/j.ccc.2013.03.004.
2.
AlbualiW.Predicting factors and outcomes of acute myocarditis in children—a 5-year experience in a teaching hospital from the Eastern province of Saudi Arabia. J Med Life. 2022;15(10):1229-1233. doi:10.25122/jml-2022-0123.
3.
NakamuraTIshidaKTaniguchiY, et al. Prognosis of patients with fulminant myocarditis managed by peripheral venoarterial extracorporeal membranous oxygenation support: a retrospective single-center study. J Intensive Care. 2015;3(1):5. doi:10.1186/s40560-014-0069-9.
4.
LiebermanEBHutchinsGMHerskowitzARoseNRBaughmanKL.Clinicopathologic description of myocarditis. J Am Coll Cardiol. 1991;18(7):1617-1626. doi:10.1016/0735-1097(91)90493-s.
5.
ChangYJChaoHCHsiaSHYanDC.Myocarditis presenting as gastritis in children. Pediatr Emerg Care. 2006;22(6):439-440. doi:10.1097/01.pec.0000221346.64991.e7.
6.
FreedmanSBHaladynJKFlohAKirshJATaylorGThull-FreedmanJ.Pediatric myocarditis: emergency department clinical findings and diagnostic evaluation. Pediatrics. 2007;120(6):1278-1285. doi:10.1542/peds.2007-1073.
7.
FerreiraVMSchulz-MengerJHolmvangG, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24):3158-3176. doi:10.1016/j.jacc.2018.09.072.
8.
RadyHIZekriH.Prevalence of myocarditis in pediatric intensive care unit cases presenting with other system involvement. J Pediatr (Rio J). 2015;91(1):93-97. doi:10.1016/j.jped.2014.05.011.
9.
AmabileNFraisseABouvenotJChetaillePOvaertC.Outcome of acute fulminant myocarditis in children. Heart. 2006;92(9):1269-1273. doi:10.1136/hrt.2005.078402.
10.
SankarJKhalilSJeeva SankarMKumarDDubeyN.Short-term outcomes of acute fulminant myocarditis in children. Pediatr Cardiol. 2011;32(7):885-890. doi:10.1007/s00246-011-0007-8.
11.
KatoSMorimotoSHiramitsuS, et al. Risk factors for patients developing a fulminant course with acute myocarditis. Circ J. 2004;68(8):734-739. doi:10.1253/circj.68.734.
12.
GhelaniSJSpaederMCPastorWSpurneyCFKlugmanD.Demographics, trends, and outcomes in pediatric acute myocarditis in the United States, 2006 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5(5):622-627. doi:10.1161/circoutcomes.112.965749.
13.
YuanJYuMLinQW, et al. Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis. J Immunol. 2010;185(7):4004-4010. doi:10.4049/jimmunol.1001718.
14.
ZhangZDaiXQiJAoYYangCLiY.Astragalus mongholicus (Fisch.) Bge improves peripheral Treg cell immunity imbalance in the children with viral myocarditis by reducing the levels of miR-146b and miR-155. Front Pediatr. 2018;6:139. doi:10.3389/fped.2018.00139.
15.
AlthofNGoetzkeCCKespohlM, et al. The immunoproteasome-specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis. EMBO Mol Med. 2018;10(2):200-218. doi:10.15252/emmm.201708089.
16.
TanGZhouQLiuK, et al. Cross-platform metabolic profiling deciphering the potential targets of Shenfu injection against acute viral myocarditis in mice. J Pharm Biomed Anal. 2018;160:1-11. doi:10.1016/j.jpba.2018.07.042.
17.
DaiKWangYTaiS, et al. Fasudil exerts a cardio-protective effect on mice with coxsackievirus B3-induced acute viral myocarditis. Cardiovasc Ther. 2018;36(6):e12477. doi:10.1111/1755-5922.12477.
18.
ZhaoYWangWYTianJ, et al. [Impact of low T3 syndrome on adverse cardiovascular events in adult patients with acute viral myocarditis]. Zhonghua Xin Xue Guan Bing Za Zhi. 2019;47(6):447-451. doi:10.3760/cma.j.issn.0253-3758.2019.06.005.
19.
JoisAZanninoDCurtisNCheungMBurgnerDPChenKYH. Arterial structure and function following viral myocarditis. Pediatr Cardiol. 2019;40(1):133-137. doi:10.1007/s00246-018-1969-6.
20.
PiaoYLLiangXC.Astragalus membranaceus injection combined with conventional treatment for viral myocarditis: a systematic review of randomized controlled trials. Chin J Integr Med. 2014;20(10):787-791. doi:10.1007/s11655-014-1825-3.
21.
ZhengQZhuangZWangZH, et al. Clinical and preclinical systematic review of Astragalus membranaceus for viral myocarditis. Oxid Med Cell Longev. 2020;2020:1560353. doi:10.1155/2020/1560353.
22.
DabaTMZhaoYPanZ.Advancement of mechanisms of coxsackie virus B3-induced myocarditis pathogenesis and the potential therapeutic targets. Curr Drug Targets. 2019;20(14):1461-1473. doi:10.2174/1389450120666190618124722.
23.
Al-BiltagiMIssaMHagarHAAbdel-HafezMAzizNA.Circulating cardiac troponins levels and cardiac dysfunction in children with acute and fulminant viral myocarditis. Acta Paediatr. 2010;99(10):1510-1516. doi:10.1111/j.1651-2227.2010.01882.x.
24.
ChenXGFengSGeWAnJD.[Comparison of prognosis in children with acute viral myocarditis induced ventricular premature beats originating from different positions and the clinical value of mgocardial perfusion ECT]. Zhongguo Dang Dai Er Ke Za Zhi. 2013;15(4):281-284.
